Reviewing Cyclacel Pharmaceuticals (NASDAQ:BGMS) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cyclacel Pharmaceuticals and Calliditas Therapeutics AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Volatility and Risk

Cyclacel Pharmaceuticals has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Institutional and Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cyclacel Pharmaceuticals and Calliditas Therapeutics AB (publ)”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$40,000.00	118.83	-$11.21 million	($81.45)	-0.01
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cyclacel Pharmaceuticals and Calliditas Therapeutics AB (publ), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Calliditas Therapeutics AB (publ)	0	0	0	0	0.00

Summary

Cyclacel Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 8 of the 12 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.